PMID: 11921427Mar 29, 2002Paper

Development of oral insulin: progress and current status

Diabetes/metabolism Research and Reviews
J Gordon Still

Abstract

NOBEX oral drug delivery technology is centered on modification of peptides, proteins and small organic molecules by attachment of one or more amphiphilic oligomers. Attachment of these oligomers results in stability to enzymatic degradation, improved solubility to allow optimized formulation, and modification of pharmacology to prolong circulating half-life and activity. NOBEX has applied this technology to insulin, creating an orally absorbed, bioactive conjugate which is safe and rapidly absorbed and which demonstrates dose-dependent, glucose-lowering effects in animal models, healthy volunteers and type 1 diabetic patients. Results of recently completed and ongoing studies in both type 1 and type 2 diabetes suggest a promising role for conjugated insulin in the management of fasting and post-prandial hyperglycemia. Orally administered conjugated insulin is delivered first to the liver through the portal circulation, similar to the physiological route of insulin secretion in non-diabetic individuals. Potential benefits from this route of insulin delivery include improved disease management and reduction of long-term complications of diabetes. Further studies with oral conjugated insulin are planned in both type 1 and type 2 ...Continue Reading

References


❮ Previous
Next ❯

Citations

Apr 6, 2004·Advanced Drug Delivery Reviews·David J Brayden, Alan W Baird
Jun 1, 2005·Archives of Medical Research·Francisco J Gómez-Pérez, Juan A Rull
Apr 9, 2005·International Journal of Pharmaceutics·Nazila Salamat-Miller, Thomas P Johnston
Jul 24, 2013·International Journal of Pharmaceutics·Pan HeXuesi Chen
Dec 19, 2003·Metabolism: Clinical and Experimental·Stephen ClementGordana Kosutic
Nov 20, 2003·Trends in Biotechnology·Samantha Lien, Henry B Lowman
Apr 23, 2004·Trends in Pharmacological Sciences·Arash NourparvarRiccardo Perfetti
Aug 24, 2004·Diabetes Technology & Therapeutics·Ehud Arbit
Jan 3, 2006·Diabetes Technology & Therapeutics·Gustaf JederströmArne Andersson
May 1, 2008·Indian Journal of Pharmaceutical Sciences·M M Al-Tabakha, A I Arida
May 8, 2013·Therapeutic Delivery·Maelíosa T C McCruddenRyan F Donnelly
Apr 6, 2013·Therapeutic Delivery·Dolores Remedios Serrano Lopez, Aikaterini Lalatsa
Nov 20, 2012·Advanced Drug Delivery Reviews·Mei-Chin ChenHsing-Wen Sung
Jul 31, 2012·Advances in Therapy·Joseph M Tibaldi
Nov 17, 2009·Expert Review of Medical Devices·Rekha M Ramesan, Chandra P Sharma
Dec 22, 2007·Drug Development and Industrial Pharmacy·Herbert HoyerAndreas Bernkop-Schnürch
Dec 22, 2007·Expert Opinion on Drug Delivery·Christiane DamgéPhilippe Maincent
May 25, 2007·Drug Development and Industrial Pharmacy·Cui TangYuanying Pei
Jul 23, 2004·Expert Opinion on Biological Therapy·Rajendra PawarAbraham J Domb
May 15, 2007·Journal of Pharmaceutical Sciences·Willi Paul, Chandra P Sharma
Apr 17, 2012·International Journal of Pharmaceutics·M R Rekha, Chandra P Sharma
Mar 15, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Francesca ButtiniGaia Colombo
Nov 17, 2011·Advanced Drug Delivery Reviews·Alessandra MaroniAndrea Gazzaniga
Nov 30, 2006·Diabetes & Metabolism·V Lassmann-Vague, D Raccah
Jan 24, 2007·Journal of Controlled Release : Official Journal of the Controlled Release Society·Kishore B ChalasaniSanjay K Jain
Aug 21, 2007·Journal of Controlled Release : Official Journal of the Controlled Release Society·Kishore B ChalasaniSanjay K Jain
Nov 25, 2003·Diabetic Medicine : a Journal of the British Diabetic Association·D R OwensG Bolli
Apr 6, 2007·Biopolymers·John P MayerRichard D DiMarchi
Oct 16, 2010·Biotechnology Progress·Partha HazraHarish Iyer
Mar 11, 2011·Biotechnology and Bioengineering·Daphne T W Ng, Casim A Sarkar
Jul 11, 2013·Macromolecular Bioscience·Weitai Wu, Shuiqin Zhou
Jul 21, 2007·Biochemical and Biophysical Research Communications·Joanne T BlanchfieldIstvan Toth
Jul 13, 2004·Journal of Controlled Release : Official Journal of the Controlled Release Society·Kathryn WhiteheadSamir Mitragotri
Jun 16, 2004·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·P CalcetiA Bernkop-Schnürch
Mar 3, 2015·Biotechnology Advances·Pedro FonteBruno Sarmento
Jun 4, 2004·Expert Opinion on Biological Therapy·Nicholas A PeppasJames O Blanchette
Jan 8, 2008·Journal of Insect Physiology·Laura A Jeffers, R Michael Roe
Apr 11, 2018·Diabetes/metabolism Research and Reviews·Pernille KihlMatthias G von Herrath

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.